Clinical Trial Update: An Oral GnRH Antagonist to Treat Mild Autonomous Cortisol Excess (MACE) Due to Adrenal Adenomas in Postmenopausal Women [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating an oral GnRH antagonist for Mild Autonomous Cortisol Excess due to adrenal adenomas in postmenopausal women was terminated, with result…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adrenal Adenoma
• Autonomous Cortisol Excess

Drugs mentioned

• Oral GnRH antagonist (investigational) (GnRH receptor antagonist)

Snippet

Sponsor: Icahn School of Medicine at Mount Sinai | Conditions: Mild Autonomous Cortisol Excess | Phase 4 | Status: TERMINATED | Results posted: 2025-03-18